About Us

Sensifree is a medical device company, on a mission to revolutionize how patients are cared for in hospitals.

We address the need for continuous blood pressure monitoring in patients going through procedures under anesthesia or conscious sedation. In the majority of the cases, blood pressure is monitored using a cuff, once every 5 minutes.
This gap in blood pressure monitoring, may cause the anesthesiologist to react late to hypotension events, that might have serious adverse effects.

We are developing continuous, noninvasive hemodynamic monitoring solutions, based on our proprietary NEST (Noninvasive Electromagnetic Sensing Technology) platform.

Our first product provides blood pressure monitoring for patients under anesthesia or procedural sedation.
The product provides beat-to-beat reading and waveform display similar to the invasive arterial line, without the risks and costs associated with it.

About Us

Sensifree is a medical device company, on a mission to revolutionize how patients are cared for in hospitals.

We address the need for continuous blood pressure monitoring in patients going through procedures under anesthesia or conscious sedation. In the majority of the cases, blood pressure is monitored using a cuff, once every 5 minutes.
This gap in blood pressure monitoring, may cause the anesthesiologist to react late to hypotension events, that might have serious adverse effects.

We are developing continuous, noninvasive hemodynamic monitoring solutions, based on our proprietary NEST (Noninvasive Electromagnetic Sensing Technology) platform.

Our first product provides blood pressure monitoring for patients under anesthesia or procedural sedation.
The product provides beat-to-beat reading and waveform display similar to the invasive arterial line, without the risks and costs associated with it.

Blood Pressure Monitoring Redefined

Achieving hemodynamic stability is crucial in improving patients’ clinical condition. Several hemodynamic parameters such as heart rate, blood pressure and cardiac output are important to monitor and control.
Abnormalities of any of these parameters may indicate hemodynamic instability which may lead to inadequate perfusion to support normal organ function.

Ideally, patients would have their blood pressure monitored continuously. This is, however, possible today only by using invasive arterial line.
The risk / benefit profile of an arterial line or contraindications for using arterial line, limit the use of it to less than 20% of the cases.

Our first product is a noninvasive and continuous blood pressure monitoring device, enabling arterial line grade monitoring for extended patient populations.
The device is risk-free, requiring a simple set up by a nurse or technician. The product consists of a disposable patch, sensor pod and a dedicated bedside monitor.

Achieving hemodynamic stability is crucial in improving patients’ clinical condition. Several hemodynamic parameters such as heart rate, blood pressure and cardiac output are important to monitor and control.
Abnormalities of any of these parameters may indicate hemodynamic instability which may lead to inadequate perfusion to support normal organ function.

Ideally, patients would have their blood pressure monitored continuously. This is, however, possible today only by using invasive arterial line.
The risk / benefit profile of an arterial line or contraindications for using arterial line, limit the use of it to less than 20% of the cases.

Our first product is a noninvasive and continuous blood pressure monitoring device, enabling arterial line grade monitoring for extended patient populations.
The device is risk-free, requiring a simple set up by a nurse or technician. The product consists of a disposable patch, sensor pod and a dedicated bedside monitor.

Relationship Between Intraoperative Hypertension and Clinical Outcomes

85%
85% of patients are monitored using intermittent cuff measurements intraoperatively, that lead to missing hypotension events
1min
Even accumulation of short durations (<1 minute) of hypotension, defined as MAP<55 mmHg, are associated with costly acute kidney injury (7.4% of cases) and myocardial injury (2.3% of cases)
$1,460
On average, those complications cost $1,460 per procedure.
By using our highly cost effective device, healthcare systems’ expenditure will be greatly reduced

NEST Platform

Our proprietary, patent pending, NEST (Noninvasive Electromagnetic Sensing Technology) platform comprises of two main elements:
1. Novel, RF based sensor technology
2. Advanced algorithmic layer to calculate and track blood pressure

Our sensor features RADAR principles to produces a unique signal from the radial artery, by tracking the distention of the pulsating blood vessel. The result is a continuous waveform that is proportional to the arterial pressure wave.

We then apply our proprietary algorithms, based on biomechanical modelling of the cardiovascular system to extract and track systolic and diastolic blood pressures, as well as mean arterial pressure (MAP).

Key benefits of the NEST Platform:
  • Noninvasive
  • Continuous waveform trace display
  • Real time calculation and tracking of blood pressure values (MAP, systolic and diastolic)
  • Early detection and alert of condition deterioration
  • Based on analytic cardiovascular model, not relying on inaccurate human parameters database
  • Place-and-forget positioning of sensor element
  • Insensitive to perfusion, temperature, complexion, vasomodulating drugs.
  • Affordable and reliable design

Our proprietary, patent pending, NEST (Noninvasive Electromagnetic Sensing Technology) platform comprises of two main elements:
1. Novel, RF based sensor technology
2. Advanced algorithmic layer to calculate and track blood pressure

Our sensor features RADAR principles to produces a unique signal from the radial artery, by tracking the distention of the pulsating blood vessel. The result is a continuous waveform that is proportional to the arterial pressure wave.

We then apply our proprietary algorithms, based on biomechanical modelling of the cardiovascular system to extract and track systolic and diastolic blood pressures, as well as mean arterial pressure (MAP).

Key benefits of the NEST Platform:
  • Noninvasive
  • Continuous waveform trace display
  • Real time calculation and tracking of blood pressure values (MAP, systolic and diastolic)
  • Early detection and alert of condition deterioration
  • Based on analytic cardiovascular model, not relying on inaccurate human parameters database
  • Place-and-forget positioning of sensor element
  • Insensitive to perfusion, temperature, complexion, vasomodulating drugs.
  • Affordable and reliable design
With every beat of the heart a pressure wave is propagating down the arteries.
The blood pressure inside the arteries is constantly changing between its systolic and diastolic values.
These changes in blood pressure cause the artery’s wall to move, and that movement is detected by our RF sensor.
With every beat of the heart a pressure wave is propagating down the arteries.
The blood pressure inside the arteries is constantly changing between its systolic and diastolic values.
These changes in blood pressure cause the artery’s wall to move, and that movement is detected by our RF sensor.

NEST Platform Parameters Breadth

Blood Pressure (BP) &
Mean Arterial Pressure (MAP)
Heart Rate (HR) &
Heart Rate Variability (HRV)
Cardiac Output (CO)
Respiration Rate (RR)
Vascular Resistance
Pulse Pressure (PP) &
Pulse Pressure Variability (PPV)
Stroke Volume (SV) &
Stroke Volume Variability (SVV)
Blood Pressure (BP) &
Mean Arterial Pressure (MAP)
Heart Rate (HR) &
Heart Rate Variability (HRV)
Cardiac Output (CO)
Respiration Rate (RR)
Vascular Resistance
Pulse Pressure (PP) &
Pulse Pressure Variability (PPV)
Stroke Volume (SV) &
Stroke Volume Variability (SVV)

Clinically Validated Sensor Technology

We recorded signals from a NEST sensor and from arterial line, the gold standard, on the same patient simultaneously and compared outcomes.

Comparison demonstrated that our sensor generates signals that are essentially as accurate as those from arterial line

News

Jun 14

2018
RHF100

CUPERTINO, CA – 6/14/2018 – Sensifree, a medical device company developing advanced RF-based hemodynamic monitoring solutions, announced today it has been selected as a finalist for Red Herring’s Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region.

The Red Herring editorial team selected the most innovative companies from a pool of hundreds from across North America. The nominees are evaluated on 20 main quantitative and qualitative criterion, which include disruptive impact, market footprint, proof of concept, financial performance, technology innovation, social value, quality of management, execution of strategy, and integration into their respective industries.

This unique assessment of potential is complemented by a review of the track record and standing of a company, which allows Red Herring to see past the “buzz” and make the list a valuable instrument for discovering and advocating the greatest business opportunities in the industry.

“This year was rewarding, beyond all expectations” said Alex Vieux, publisher and CEO of Red Herring. “There are many great companies generating really innovative and disruptive products in North America. We had a very difficult time narrowing the pool and selecting the finalists. Sensifree shows great promise and therefore deserves to be among the finalists. Now we’re faced with the difficult task of selecting the Top 100 winners of Red Herring North America. We know that the 2018 crop will grow into some amazing companies that are sure to make an impact.”

Finalists for the 2018 edition of the Red Herring 100 North America award are selected based upon their technological innovation, management strength, market size, investor record, customer acquisition, and financial health. During the months leading up to the announcement, Red Herring reviewed over 1200 companies in the telecommunications, security, cloud, software, hardware, biotech, mobile and other industries that completed their submissions to qualify for the award.

Sensifree’s CEO, Eran Agmon, will present at the Red Herring North America Forum in Marina Del Rey, June 18-20, 2018. The Top 100 winners will be announced at a special awards ceremony on the evening of June 20 at the event.

Jan 05

2018

CUPERTINO, Calif.–(BUSINESS WIRE)–Sensifree, a medical device company developing advanced RF-based hemodynamic monitoring solutions, announces results of a clinical study showing excellent concordance between the signal morphology of its RF based sensor and invasive arterial line, the standard of care for continuous blood pressure monitoring. Clinical data from the study further validate blood pressure extraction and tracking algorithms. Preliminary results demonstrate accurate tracking of systolic and diastolic pressure values.

Jan 23

2017

Neuchâtel (CH), Cupertino, CA (US), and Petach-Tikva (IL); January 23, 2017—Sensifree and CSEM join forces to create a disruptive technology for monitoring blood pressure without using a cuff. Combining CSEM’s expertise in the field of blood pressure monitoring and Sensifree’s novel, RF-based approach will pave the way for the production of a new tool for the highly attractive health wearables market.

Sep 20

2016

Sensifree Ltd. (Cupertino, Calif.) was founded in 2012 and claims to have developed a contact free, electromagnetic sensor that accurately collect a range of continuous biometric data without the need to touch the human body. The Sensifree technology uses RF signal to sense movement in the radial artery wall to track heart rate, and in the future blood pressure. Having taken the pulse digital signal processing is used to extract more information.

May 24

2016
Sensifree Secures $5M in Series A Financing Led by TransLink Capital 

Cupertino, CA and Petach-Tikva, Israel, May 24, 2016 — Sensifree, the pioneer in low power, contact free, electromagnetic sensors that accurately collect a range of continuous biometric data without the need to touch the human body, today announced it has completed a $5.0 million Series A round of financing. TransLink Capital led the investment round with participation from existing and new investors, including UMC Capital, a subsidiary of United Microelectronics Corp. (NYSE: UMC) and an undisclosed strategic investor.

Meet The Team

Eran Agmon | CEO & Co-founder

Eran is a veteran of the technology industry, with over 20 years of experience in various companies, both mature and startups, in which he held executive and senior level positions in corporate development, product strategy and marketing.
Eran brings with him proven experience in developing new businesses from scratch, with strong multi disciplinary technical background. Eran holds a B.Sc.EE degree from the Tel-Aviv University. Prior to founding Sensifree, Eran worked at Gilat Satellite Networks, Camero-Tech and Raysat Antenna Systems.

llan Barak | CTO & Co-founder

Ilan is an expert in microwaves, RF and chip design. With over 35 years of experience in the Israeli hi-tech industry and more than 20 patents filed by him, Ilan leads the technological innovation in Sensifree.
Ilan holds B.Sc. and M.Sc. degrees in electrical engineering, both from the Tel-Aviv University. Prior to founding Sensifree, Ilan worked at Gilat Satellite Networks, Intel and Raysat Antenna Systems.

Lior Haviv | COO & Head of R&D

Lior is a technology executive with 25 years of experience in R&D and corporate management in senior level positions, covering a wide range of systems, hardware and software disciplines, with significant involvement in operations, QA and pre and post-sales support. Prior to joining Sensifree, Lior worked at Gilat Satellite Networks, EMC2 and Channelot.

Moshe Kamar, MD | CMO

Dr. Kamar is a board certified practicing general surgeon, with vast hands on experience in clinical and medical affairs, designing and overseeing multiple large scale clinical trials and FDA submissions.
Dr. Kamar also worked for Ornim Medical, Omrix Biopharmaceuticals, Johnson and Johnson and Teva Pharmaceuticals.

Asaf Bar | VP, BD & Marketing

Asaf has over 16 years of business development, marketing and finance senior level roles in medical devices and biopharma companies.
His experience includes strategic planning and execution, product development and launch and crafting partnerships.
Asaf worked also for Johnson and Johnson, Omrix Biopharmaceuticals, Lumenis and PolyPid.

Benny Zeevi, MD | Managing General Partner, Tel Aviv Venture Partners

Dr. Benny Zeevi is an interventional pediatric cardiologist and leads the fund life science investments. He is a prominent figure and deeply involved in the Israeli life sciences and digital health industries. Dr. Zeevi is the chairman of the board of several companies and advisor to other companies. Dr. Zeevi holds an MD degree (Magna Cum Laude) from the Sackler School of Medicine, Tel Aviv University, Israel.

Eric Hsia | Venture Partner, Translink Capital

Eric leads TransLink’s activities supporting portfolio companies with their customers and partners, primarily in Greater China. He is interested in companies at the intersection of health and information technology, finance and technology, and consumer services. Eric is a founder of Eternal Capital and a private investor, board member, and advisor to public and private technology companies. He earned a B.A. in Economics from Harvard College.

Eran Agmon | CEO & Co-founder

Eran is a veteran of the technology industry, with over 20 years of experience in various companies, both mature and startups, in which he held executive and senior level positions in corporate development, product strategy and marketing. Eran brings with him proven experience in developing new businesses from scratch, with strong multi disciplinary technical background. Eran holds a B.Sc.EE degree from the Tel-Aviv University. Prior to founding Sensifree, Eran worked at Gilat Satellite Networks, Camero-Tech and Raysat Antenna Systems.

llan Barak | CTO & Co-founder

Ilan is an expert in microwaves, RF and chip design. With over 35 years of experience in the Israeli hi-tech industry and more than 20 patents filed by him, Ilan leads the technological innovation in Sensifree. Ilan holds B.Sc. and M.Sc. degrees in electrical engineering, both from the Tel-Aviv University. Prior to founding Sensifree, Ilan worked at Gilat Satellite Networks, Intel and Raysat Antenna Systems.

James Welch | Regulatory & QA Advisor

James has 45 years of experience in the clinical application, development and regulatory approvals of non-invasive vital signs measurements, including blood pressure monitoring devices, while he held executive positions at Protocol Systems, Welch Allyn, Masimo, and Sotera Wireless. He is an expert in product development, quality systems and regulatory affairs.

Arthur Wallace, MD | Medical Advisor

Dr. Wallace is a professor and vice-chair of anesthesiology and perioperative care at the University of California, San Francisco and Chief of the Anesthesia Service at the Veterans Affairs Medical Center in San Francisco. He completed a B.S. in engineering and applied science with a specialty in electrical engineering at Yale. He then completed an M.D. and Ph.D. at Johns Hopkins Medical School with his Ph.D. in biomedical engineering with research in systems physiology and autonomic control of the vasculature.

Contact Us

Headquarters
21631 Stevens Creek Blvd. Suite B,
Cupertino, CA 95014, USA
Tel: +1-669-230-5116

R&D Center
10 Hamefalsim St.,
Petah Tikva 4951420, Israel
Tel: +972-3-559-8990